Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Mutation-Induced Functional Alterations of CCR6.

Julian B, Gao K, Harwood BN, Beinborn M, Kopin AS.

J Pharmacol Exp Ther. 2017 Jan;360(1):106-116. Epub 2016 Oct 27.

PMID:
27789680
2.

Novel Probes Establish Mas-Related G Protein-Coupled Receptor X1 Variants as Receptors with Loss or Gain of Function.

Heller D, Doyle JR, Raman VS, Beinborn M, Kumar K, Kopin AS.

J Pharmacol Exp Ther. 2016 Feb;356(2):276-83. doi: 10.1124/jpet.115.227058. Epub 2015 Nov 18.

PMID:
26582731
3.

A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substrates.

Heard KR, Wu W, Li Y, Zhao P, Woznica I, Lai JH, Beinborn M, Sanford DG, Dimare MT, Chiluwal AK, Peters DE, Whicher D, Sudmeier JL, Bachovchin WW.

J Med Chem. 2013 Nov 14;56(21):8339-51. doi: 10.1021/jm400423p. Epub 2013 Oct 16.

PMID:
24044354
4.

Membrane tethered bursicon constructs as heterodimeric modulators of the Drosophila G protein-coupled receptor rickets.

Harwood BN, Fortin JP, Gao K, Chen C, Beinborn M, Kopin AS.

Mol Pharmacol. 2013 Apr;83(4):814-21. doi: 10.1124/mol.112.081570. Epub 2013 Jan 22.

5.

Naturally occurring HCA1 missense mutations result in loss of function: potential impact on lipid deposition.

Doyle JR, Lane JM, Beinborn M, Kopin AS.

J Lipid Res. 2013 Mar;54(3):823-30. doi: 10.1194/jlr.M034660. Epub 2012 Dec 24.

6.

Selected melanocortin 1 receptor single-nucleotide polymorphisms differentially alter multiple signaling pathways.

Doyle JR, Fortin JP, Beinborn M, Kopin AS.

J Pharmacol Exp Ther. 2012 Aug;342(2):318-26. doi: 10.1124/jpet.112.194548. Epub 2012 Apr 30.

7.

Discovery of dual-action membrane-anchored modulators of incretin receptors.

Fortin JP, Chinnapen D, Beinborn M, Lencer W, Kopin AS.

PLoS One. 2011;6(9):e24693. doi: 10.1371/journal.pone.0024693. Epub 2011 Sep 14.

8.

Two naturally occurring mutations in the type 1 melanin-concentrating hormone receptor abolish agonist-induced signaling.

Goldstein C, Schroeder JC, Fortin JP, Goss JM, Schaus SE, Beinborn M, Kopin AS.

J Pharmacol Exp Ther. 2010 Dec;335(3):799-806. doi: 10.1124/jpet.110.174029. Epub 2010 Sep 10.

9.

The μ-opioid receptor variant N190K is unresponsive to peptide agonists yet can be rescued by small-molecule drugs.

Fortin JP, Ci L, Schroeder J, Goldstein C, Montefusco MC, Peter I, Reis SE, Huggins GS, Beinborn M, Kopin AS.

Mol Pharmacol. 2010 Nov;78(5):837-45. doi: 10.1124/mol.110.064188. Epub 2010 Aug 11.

10.

TGF-beta regulates T-cell neurokinin-1 receptor internalization and function.

Beinborn M, Blum A, Hang L, Setiawan T, Schroeder JC, Stoyanoff K, Leung J, Weinstock JV.

Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4293-8. doi: 10.1073/pnas.0905877107. Epub 2010 Feb 16.

11.

Pharmacological characterization of human incretin receptor missense variants.

Fortin JP, Schroeder JC, Zhu Y, Beinborn M, Kopin AS.

J Pharmacol Exp Ther. 2010 Jan;332(1):274-80. doi: 10.1124/jpet.109.160531. Epub 2009 Oct 19.

12.

Neurogenin 3-specific dipeptidyl peptidase-2 deficiency causes impaired glucose tolerance, insulin resistance, and visceral obesity.

Danilova OV, Tai AK, Mele DA, Beinborn M, Leiter AB, Greenberg AS, Perfield JW 2nd, Defuria J, Singru PS, Lechan RM, Huber BT.

Endocrinology. 2009 Dec;150(12):5240-8. doi: 10.1210/en.2009-0386. Epub 2009 Oct 9.

13.

Membrane-tethered ligands are effective probes for exploring class B1 G protein-coupled receptor function.

Fortin JP, Zhu Y, Choi C, Beinborn M, Nitabach MN, Kopin AS.

Proc Natl Acad Sci U S A. 2009 May 12;106(19):8049-54. doi: 10.1073/pnas.0900149106. Epub 2009 Apr 23.

14.

Seeking for alpha-helical propensity in a receptor-bound conformation of glucagon-like peptide-1.

Murage E, Beinborn M, Ahn JM.

Adv Exp Med Biol. 2009;611:289-90. No abstract available.

PMID:
19400196
15.

Rational design of peptidomimetics for class B GPCRs: potent non-peptide GLP-1 receptor agonists.

Ahn JM, Han SY, Murage E, Beinborn M.

Adv Exp Med Biol. 2009;611:125-6. No abstract available.

PMID:
19400122
16.

Facile synthesis of glucagon-like peptide-1 (GLP-1) mimetics.

Han SY, Beinborn M, Ahn JM.

Adv Exp Med Biol. 2009;611:119-20. No abstract available.

PMID:
19400120
17.

Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1.

Murage EN, Schroeder JC, Beinborn M, Ahn JM.

Bioorg Med Chem. 2008 Dec 1;16(23):10106-12. doi: 10.1016/j.bmc.2008.10.006. Epub 2008 Oct 5.

PMID:
18952440
18.

Influence of selective fluorination on the biological activity and proteolytic stability of glucagon-like peptide-1.

Meng H, Krishnaji ST, Beinborn M, Kumar K.

J Med Chem. 2008 Nov 27;51(22):7303-7. doi: 10.1021/jm8008579.

19.

Pharmacological analysis of human D1 AND D2 dopamine receptor missense variants.

Al-Fulaij MA, Ren Y, Beinborn M, Kopin AS.

J Mol Neurosci. 2008 Mar;34(3):211-23. doi: 10.1007/s12031-007-9030-x. Epub 2008 Jan 18.

PMID:
18210231
20.

Four missense mutations in the ghrelin receptor result in distinct pharmacological abnormalities.

Liu G, Fortin JP, Beinborn M, Kopin AS.

J Pharmacol Exp Ther. 2007 Sep;322(3):1036-43. Epub 2007 Jun 27.

PMID:
17596538
21.

Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function.

Al-Fulaij MA, Ren Y, Beinborn M, Kopin AS.

J Pharmacol Exp Ther. 2007 Apr;321(1):298-307. Epub 2007 Jan 4.

PMID:
17204745
22.

Point mutations in either subunit of the GABAB receptor confer constitutive activity to the heterodimer.

Mukherjee RS, McBride EW, Beinborn M, Dunlap K, Kopin AS.

Mol Pharmacol. 2006 Oct;70(4):1406-13. Epub 2006 Jul 17.

PMID:
16847143
23.

Class B GPCRs: a hidden agonist within?

Beinborn M.

Mol Pharmacol. 2006 Jul;70(1):1-4. Epub 2006 Apr 21.

PMID:
16632645
24.

Ménétrier's disease in a patient with Helicobacter pylori infection is linked to elevated glucagon-like peptide-2 activity.

Watanabe K, Beinborn M, Nagamatsu S, Ishida H, Takahashi S.

Scand J Gastroenterol. 2005 Apr;40(4):477-81.

PMID:
16028444
25.

A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness.

Beinborn M, Worrall CI, McBride EW, Kopin AS.

Regul Pept. 2005 Aug 15;130(1-2):1-6.

PMID:
15975668
26.

Basal receptor activation by locally produced glucagon-like peptide-1 contributes to maintaining beta-cell function.

Masur K, Tibaduiza EC, Chen C, Ligon B, Beinborn M.

Mol Endocrinol. 2005 May;19(5):1373-82. Epub 2005 Jan 27.

PMID:
15677711
27.

Interleukin-1 upregulates anaphylatoxin receptors on mononuclear cells.

Takabayashi T, Shimizu S, Clark BD, Beinborn M, Burke JF, Gelfand JA.

Surgery. 2004 May;135(5):544-54.

PMID:
15118592
28.

Ligand function at constitutively active receptor mutants is affected by two distinct yet interacting mechanisms.

Beinborn M, Ren Y, Bläker M, Chen C, Kopin AS.

Mol Pharmacol. 2004 Mar;65(3):753-60.

PMID:
14978254
29.

Conserved cholecystokinin receptor transmembrane domain IV amino acids confer peptide affinity.

Ren Y, Bläker M, Seshadri L, McBride EW, Beinborn M, Kopin AS.

J Mol Neurosci. 2003 Apr;20(2):115-24.

PMID:
12794305
30.

Established theory of radiation-induced decay is not generalizable to Bolton-Hunter labeled peptides.

Doran AC, Wan YP, Kopin AS, Beinborn M.

Biochem Pharmacol. 2003 May 1;65(9):1515-20.

PMID:
12732364
31.

Identification of a series of CCK-2 receptor nonpeptide agonists: sensitivity to stereochemistry and a receptor point mutation.

Kopin AS, McBride EW, Chen C, Freidinger RM, Chen D, Zhao CM, Beinborn M.

Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5525-30. Epub 2003 Apr 15.

32.

A Drosophila dopamine 2-like receptor: Molecular characterization and identification of multiple alternatively spliced variants.

Hearn MG, Ren Y, McBride EW, Reveillaud I, Beinborn M, Kopin AS.

Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14554-9. Epub 2002 Oct 21.

33.

A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain.

Tibaduiza EC, Chen C, Beinborn M.

J Biol Chem. 2001 Oct 12;276(41):37787-93. Epub 2001 Aug 9.

34.

Investigation of gastroprotective compounds at subcellular level in isolated gastric mucosal cells.

Nagy L, Morales RE, Beinborn M, Vattay P, Szabo S.

Am J Physiol Gastrointest Liver Physiol. 2000 Dec;279(6):G1201-8.

35.

Inhibition of morphine tolerance development by a substance P-opioid peptide chimera.

Foran SE, Carr DB, Lipkowski AW, Maszczynska I, Marchand JE, Misicka A, Beinborn M, Kopin AS, Kream RM.

J Pharmacol Exp Ther. 2000 Dec;295(3):1142-8.

PMID:
11082451
36.

CCK receptor polymorphisms: an illustration of emerging themes in pharmacogenomics.

Kopin AS, McBride EW, Schaffer K, Beinborn M.

Trends Pharmacol Sci. 2000 Sep;21(9):346-53. Review.

PMID:
10973088
37.

CCK-B/Gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides.

Bläker M, Ren Y, Seshadri L, McBride EW, Beinborn M, Kopin AS.

Mol Pharmacol. 2000 Aug;58(2):399-406.

PMID:
10908308
38.

A substance P-opioid chimeric peptide as a unique nontolerance-forming analgesic.

Foran SE, Carr DB, Lipkowski AW, Maszczynska I, Marchand JE, Misicka A, Beinborn M, Kopin AS, Kream RM.

Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7621-6.

39.

Abnormal gastric morphology and function in CCK-B/gastrin receptor-deficient mice.

Rindi G, Langhans N, Rehfeld JF, Beinborn M, Kopin AS.

Yale J Biol Med. 1998 May-Aug;71(3-4):347-54.

40.

Small synthetic ligands of the cholecystokinin-B/gastrin receptor can mimic the function of endogenous peptide hormones.

Beinborn M, Chen C, DeMeo L, McBride EW, Kopin AS.

Yale J Biol Med. 1998 May-Aug;71(3-4):337-46.

41.

The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight.

Kopin AS, Mathes WF, McBride EW, Nguyen M, Al-Haider W, Schmitz F, Bonner-Weir S, Kanarek R, Beinborn M.

J Clin Invest. 1999 Feb;103(3):383-91. Erratum in: J Clin Invest 1999 Mar;103(5):759.

42.

Mutations within the cholecystokinin-B/gastrin receptor ligand 'pocket' interconvert the functions of nonpeptide agonists and antagonists.

Bläker M, Ren Y, Gordon MC, Hsu JE, Beinborn M, Kopin AS.

Mol Pharmacol. 1998 Nov;54(5):857-63.

PMID:
9804620
43.

Interspecies polymorphisms confer constitutive activity to the Mastomys cholecystokinin-B/gastrin receptor.

Schaffer K, McBride EW, Beinborn M, Kopin AS.

J Biol Chem. 1998 Oct 30;273(44):28779-84.

44.
45.

Inter- and intraspecies polymorphisms in the cholecystokinin-B/gastrin receptor alter drug efficacy.

Kopin AS, McBride EW, Gordon MC, Quinn SM, Beinborn M.

Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):11043-8.

46.

Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice.

Langhans N, Rindi G, Chiu M, Rehfeld JF, Ardman B, Beinborn M, Kopin AS.

Gastroenterology. 1997 Jan;112(1):280-6.

PMID:
8978369
47.

Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor.

Schmitz F, Pratt DS, Wu MJ, Kolakowski LF Jr, Beinborn M, Kopin AS.

Mol Pharmacol. 1996 Aug;50(2):436-41.

PMID:
8700154
48.

Characterization of CCKA receptor mediated pepsinogen secretion in porcine chief cells.

Meyer G, Beinborn M, Sewing KF.

Pharmacology. 1996 Jul;53(1):48-59.

PMID:
8875601
49.

Purinoceptor P2U identification and function in human intrahepatic biliary epithelial cell lines.

Wolkoff LI, Perrone RD, Grubman SA, Lee DW, Soltoff SP, Rogers LC, Beinborn M, Fang SL, Cheng SH, Jefferson DM.

Cell Calcium. 1995 May;17(5):375-83.

PMID:
7553790
50.

The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective ligands.

Kopin AS, McBride EW, Quinn SM, Kolakowski LF Jr, Beinborn M.

J Biol Chem. 1995 Mar 10;270(10):5019-23.

Supplemental Content

Loading ...
Support Center